JB Buse, C Weyer, DG Maggs - Clinical Diabetes, 2002 - Am Diabetes Assoc Long-term intervention studies such as the Diabetes Control and Complications
Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have
clearly demonstrated that intensification of diabetes therapy reduces the ... Cited by 42 - Related articles - BL Direct - All 2 versions
SV Edelman, C Weyer - Diabetes Technology & Therapeutics, 2002 - liebertonline.com Current insulin therapy still fails to safely restore near-normoglycemia in the
majority of pa- tients. Among the barriers to achieving tight long-term glycemic
control with insulin in both type 1 and type 2 diabetes are an increased ... Cited by 48 - Related articles - BL Direct - All 4 versions
M Fineman, C Weyer, DG Maggs, S Strobel, … - Hormone and metabolic research, 2002 - thieme-connect.com Aims: Amylin is a second beta-cell hormone that is normally co-secreted with
insulin in response to meals; it complements the effects of insulin in
postprandial glucose control, in part by suppressing glucagon secretion. In ... Cited by 92 - Related articles - BL Direct - All 10 versions
C Weyer, DG Maggs, AA Young, OG … - Current pharmaceutical design, 2001 - ingentaconnect.com Abstract: Destruction and dysfunction of pancreatic beta-cells, resulting in
absolute and relative insulin deficiency, represent key abnormalities in the
pathogenesis of type 1 and type 2 diabetes, respectively. Following the ... Cited by 75 - Related articles - BL Direct - All 3 versions
[CITATION] Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people …
MF Kong, TA Stubbs, P King, IA Macdonald, … - Diabetologia, 1998 - Springer Gastric emptying is a significant determinant of the blood glucose response
after an oral carbohydrate load [1] due to the key role this process plays in
regu- lating the rate of nutrient delivery to the small intes- tine. ... Cited by 58 - Related articles - BL Direct - All 3 versions
[CITATION] Amylin response following Sustacal® ingestion is diminished in type II diabetic patients …
- ►diabetesjournals.org PA Hollander, P Levy, MS Fineman, DG Maggs … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Treatment with pramlintide 120 μg BID led to a sustained reduction
from baseline in HbA 1c (−0.68 and −0.62% at weeks 26 and 52, respectively),
which was significantly greater than that seen with placebo (P < 0.05). The ... Cited by 167 - Related articles - BL Direct - All 5 versions
F Whitehouse, DF Kruger, M Fineman, L … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Treatment with pramlintide led to a mean reduction in HbA 1c of 0.67%
from baseline to week 13 that was significantly (P < 0.0001) greater than the
placebo reduction (0.16%), and a significant placebo-corrected treatment ... Cited by 135 - Related articles - BL Direct - All 6 versions
